ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1092
-0,28%
Bitcoin
70.177,24
0,07%
Brent Oil
82,36
-0,10%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Adagio Therapeutics Inc (ADGI)

  7. Adagio Therapeutics Inc (ADGI) Notícias

ADGI

Adagio Therapeutics (ADGI)

Adagio Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ADGI
DataHoraFonteTítuloCódigoCompanhia
29/06/202308:09Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADGIAdagio Therapeutics Inc
25/05/202319:44Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ADGIAdagio Therapeutics Inc
12/04/202317:47Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ADGIAdagio Therapeutics Inc
10/04/202317:20Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ADGIAdagio Therapeutics Inc
10/04/202317:11Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ADGIAdagio Therapeutics Inc
10/04/202317:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ADGIAdagio Therapeutics Inc
31/03/202317:38Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ADGIAdagio Therapeutics Inc
23/03/202317:31Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ADGIAdagio Therapeutics Inc
09/02/202313:48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ADGIAdagio Therapeutics Inc
19/12/202209:00GlobeNewswire Inc.Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA WorkshopNASDAQ:ADGIAdagio Therapeutics Inc
06/12/202218:01GlobeNewswire Inc.Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical OfficerNASDAQ:ADGIAdagio Therapeutics Inc
29/11/202219:17Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:ADGIAdagio Therapeutics Inc
10/11/202218:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ADGIAdagio Therapeutics Inc
06/10/202207:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ADGIAdagio Therapeutics Inc
12/09/202208:15GlobeNewswire Inc.Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron VariantsNASDAQ:ADGIAdagio Therapeutics Inc
12/09/202208:00GlobeNewswire Inc.Adagio Therapeutics Announces Corporate Name Change to InvivydNASDAQ:ADGIAdagio Therapeutics Inc
06/09/202217:01GlobeNewswire Inc.Adagio Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:ADGIAdagio Therapeutics Inc
19/08/202218:23Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ADGIAdagio Therapeutics Inc
15/08/202207:30GlobeNewswire Inc.Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsNASDAQ:ADGIAdagio Therapeutics Inc
05/07/202209:00Business WireMithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy CampaignNASDAQ:ADGIAdagio Therapeutics Inc
05/07/202208:25GlobeNewswire Inc.Adagio Announces David Hering Named Permanent Chief Executive Officer and DirectorNASDAQ:ADGIAdagio Therapeutics Inc
01/07/202207:30GlobeNewswire Inc.Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of DirectorsNASDAQ:ADGIAdagio Therapeutics Inc
06/06/202207:03Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:ADGIAdagio Therapeutics Inc
02/06/202217:25Edgar (US Regulatory)Information Statement - Contested Solicitations (definitive) (defc14c)NASDAQ:ADGIAdagio Therapeutics Inc
19/05/202218:07Edgar (US Regulatory)Information Statement - Contested Solicitations (preliminary) (prec14c)NASDAQ:ADGIAdagio Therapeutics Inc
19/05/202217:31ValueWalkAdagio Therapeutics Jumps 629 Ranks To 119th Most Owned Stock On The PlatformNASDAQ:ADGIAdagio Therapeutics Inc
17/05/202209:45TipRanksAdagio Therapeutics (ADGI) Gets a Sell Rating from Morgan StanleyNASDAQ:ADGIAdagio Therapeutics Inc
13/05/202211:26Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ADGIAdagio Therapeutics Inc
13/05/202207:30GlobeNewswire Inc.Adagio Therapeutics Reports First Quarter 2022 Financial ResultsNASDAQ:ADGIAdagio Therapeutics Inc
29/04/202218:22Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ADGIAdagio Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ADGI

Seu Histórico Recente

NASDAQ
WDBDAX
WTCCIF II World
AQSE
GWIN
Gowin New Energy
AQSE
SXLP.GB
State Street Global Advi...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados